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ABSTRACT 
Objectives: To externally validate and compare the two novel versions of the 
ERSPC- prostate cancer (PCa) risk-calculator (RC) and PCPT-RC. 
Patients and methods: All men who underwent a transrectal prostate biopsy in a 
European tertiary care centre between 2004 and 2012 were retrospectively identified.  
The probability of detecting PCa and significant PCa (Gleason score ≥7) was 
calculated for each man using the novel versions of the ERSPC-RC (DRE-based 
version 3 / 4) and the PCPT-RC (version 2.0) and compared with the biopsy results. 
Calibration and discrimination were assessed using the calibration slope method and 
the area under the receiver operating characteristic curve (AUC), respectively. 
Additionally, decision curve analyses were performed. 
Results: Of 1996 men, 483 (24%) were diagnosed with PCa and 226 (11%) with 
significant PCa. Calibration of the two RCs was comparable, although the PCPT-RC 
was slightly superior in the higher risk prediction range for any and significant PCa. 
Discrimination of the ERSPC- and PCPT-RC was comparable for any PCa (AUCs: 
0.65 vs. 0.66), while the ERSPC-RC was somewhat better for significant PCa (AUCs: 
0.73 vs. 0.70). Decision curve analyses revealed a comparable net benefit for any 
PCa and a slightly greater net benefit for significant PCa using the ERSPC-RC.  
Conclusions: In our independent external validation, both updated RCs showed less 
optimistic performance compared to their original reports particularly for the 
prediction of any PCa. Risk prediction of significant PCa, which is important to avoid 
unnecessary biopsies and reduce overdiagnosis and overtreatment, was better for 
both RCs and slightly superior using the ERSPC-RC. 
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Introduction 
The widespread use of prostate-specific antigen (PSA) testing led to an increased 
prostate cancer (PCa) detection rate and a shift from advanced to earlier disease 
states at diagnosis [1]. Earlier PCa treatment is thought to have contributed to the 
reduced incidence of advanced and metastatic disease and PCa-specific mortality [2, 3].  
Classically, a serum PSA value above a pre-defined threshold or a suspicious digital 
rectal examination (DRE) triggered the decision to perform a prostate biopsy. 
However, the limited sensitivity and specificity of PSA and DRE alone resulted in a 
high number of negative, thus unnecessary biopsies [4]. Furthermore, PSA-based 
screening also increased the detection of potentially indolent PCa, which often does 
not become clinically relevant even when left untreated [5, 6]. Diagnosis and 
subsequent treatment of insignificant PCa can be regarded as overdiagnosis and 
overtreatment [5]. In screen-detected cohorts, the estimates of PCa overdiagnosis 
range from 23% to 44% [1]. 
Numerous nomogram-based PCa risk-calculators (RC) have been developed to 
improve risk-prediction and to overcome the problems of unnecessary biopsies, 
overdiagnosis and overtreatment [7-10]. It has been shown that these RCs are more 
accurate in predicting the likelihood of PCa detection than PSA and DRE alone [7, 11].  
The ERSPC-RC and the PCPT-RC are two well-known PCa RCs based on data from 
the Dutch arm of the European Randomized Study for Screening of Prostate Cancer 
(ERSPC, 15’758 men) and the placebo arm of the Prostate Cancer Prevention Trial 
(PCPT, 5’519 men), respectively [8, 9]. Both RCs have been extensively validated in 
independend cohorts with distinct variation in performance among the different 
validation cohorts [12-16]. Modifications of the original versions of both RCs have 
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constantly been performed to improve their performance. Recently, novel versions of 
both RCs have been launched and promising results in development and validation 
cohorts have been reported in their original publications [17, 18]. So far, only one 
small independent validation study of these novel versions has been performed. 
However, to date, an independent validation and comparison in an adequately large 
patient cohort has not been conducted [19]. The aim of the present investigation was 
to independently validate and compare the performance of the two updated RCs. 
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Patients and methods 
All men who underwent a transrectal ultrasound (TRUS)-guided prostate biopsy between 
January 2004 and July 2012 in a European tertiary care academic centre, were 
retrospectively identified. Pre-biopsy clinical and pathological data were obtained from 
electronic medical charts. Patients were excluded if they were older than 75 years, if their 
PSA was >50μg/l or if they had a previous positive biopsy (i.e. under active surveillance). 
Men with previous negative biopsies were included. This study was approved by the local 
ethics committee (approval no.: StV-Nr.0133/2012). 
Generally, a prostate biopsy was considered if serum PSA was 2.5μg/l or greater or if a 
DRE was abnormal. Before 2007 either six- or eight-core biopsies and after 2007 only 
twelve-core biopsies were performed. Histological examination took place in our Institute of 
Surgical Pathology. 
The probabilities of detection of PCa and significant PCa (Gleason Score ≥7) were 
calculated for each patient using the novel DRE-based ERSPC-RC (www.prostatecancer-
riskcalculator.com) [8, 18] and the novel version of the PCPT-RC (version 2.0; 
http://deb.uthscsa.edu/URORiskCalc/Pages/calcs.jsp) [17]. The calculated probabilities 
were compared with the actual biopsy results for the entire cohort.  
The novel ERSPC-RC is based on three variables (PSA, prostate volume and suspicious 
DRE; Table 1). The variable prostate volume is a DRE-based estimate trichotomized into 
three volumes (25ml, 40ml and 60ml). For our analysis, TRUS-measured prostate volume 
was used and trichotomized according to the predifined volumes of the RC (TRUS volume 
<30ml = 25ml, 30-50ml = 40ml and ≥50ml = 60ml). Risk calculation for biopsy-naïve 
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patients was done using the ERSPC-RC version 3+DRE. For patients with previous 
negative biopsies the RC version 4+DRE was used.  
The novel PCPT-RC 2.0 is based on seven variables (Table 1) and gives separate 
predictions for not being diagnosed with PCa (no PCa) and for being diagnosed with 
insignificant PCa (Gleason score 6) and significant PCa. To compare the PCPT-RC 2.0 with 
the ERSPC-RC the prediction results had to be dichotomized: the risk of being diagnosed 
with any PCa was calculated from significant or insignificant PCa versus no PCa and the 
risk of being diagnosed with significant PCa was calculated from significant versus no or 
insignificant PCa.  
Statistical analyses were performed using R statistical software version 3.1.0 (http://www.r-
project.org). Associations between clinical and pathological variables were assessed using 
the chi-square test for categorical variables and the Wilcoxon rank-sum test for continuous 
variables. All p-values <0.05 were considered statistically significant. Missing values (n=53 
for prostate volume) were single-imputed using the mice algorithm [20]. 
Calibration and discrimination were assessed for each RC. Calibration refers to the 
agreement between the predicted and observed proportion of events. Calibration was 
assessed graphically using a calibration plot and calibration-in-the-large. In a calibration 
plot, the predicted probabilities are plotted against the observed probabilities, allowing to 
assess the extent of risk over- or underestimation. The predicted probability refers to the 
probability of PCa for a given patient calculated for each RC. Patients were divided into 
quintiles (each group n=399) of predicted risk. Calibration-in-the-large was calculated by 
fitting a logistic regression model with the linear predictor of the models as an offset. The 
resulting intercept indicates whether predictions are systematically too low or too high. The 
calibration slope is a measure of the average strength of the predictors in a prediction 
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model and was obtained by fitting a logistic regression model with the linear predictor of the 
model as only covariate.  
Discrimination refers to the ability of a prediction model to distinguish between patients with 
and without an event (any PCa or significant PCa) and was quantified using the area under 
the receiver operating characteristic curve (AUC). The AUCs of the ERSPC-RC and PCPT-
RC 2.0 were compared using the method of DeLong and colleagues [21].  
Additionally, decision curve analyses (DCAs) were performed for the assessment of the net 
benefit according to different threshold probabilities at which one would consider to perform 
a biopsy [22]. A probability threshold in a decision curve is different to the predicted 
probability in a calibration curve and refers to the a-priori cut point at which the clinician 
would do a biopsy. 
In order to assess whether the number of biopsy cores taken impacted the performance of 
the novel RCs we performed a sensitivity analysis for patients who had either 6-8-core 
biospies or 12-core biopsies.  
Additionally we aimed to analyze whether the performance of the novel versions of the two 
RCs are superior to their previous versions. For the ERSPC-RC we were not able to 
perform this analysis because the previous version include the variable suspicious TRUS 
lesion, which was not available in our dataset. However, for the two older versions of the 
PCPT-RC (original RC-1.0, RC-1.0 plus prostate volume; for details see Supplemental 
Table 1) we were able to perform the above mentioned analyses to asses differences in risk 
prediction of the different versions.  
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Results 
Of 2304 identified men, 308 were excluded due to age >75 years, PSA >50μg/l or previous 
positive biopsies, resulting in 1996 men eligible for the final analysis. Table 2 summarizes 
their baseline characteristics. Overall, 1151 men (58%) were biopsy-naïve. PCa was 
detected in 483 men (24%) of which 226 (47%) had significant disease. Men with PCa were 
significantly older, had smaller prostates and higher PSA values. Furthermore, they were 
more likely to have a positive family history, a suspicious DRE but less likely to have a 
previous negative biopsy (Table 2). 
The predicted proportions of any PCa and significant PCa were comparable between the 
ERSPC-RC and PCPT-RC 2.0 and were close to the observed proportion (Table 3).  
The calibration plots of the ERSPC-RC showed good calibration in the risk range between 0 
and 0.4 for both outcomes (Figures 1A, 2A). The calibration plots for the PCPT-RC 2.0 
showed good calibration for both outcomes over the whole prediction range (Figures 1B, 
2B). The calibration slope of the ERSPC-RC was lower than one, indicating that the effects 
of the predictors were on average too strong (Table 4). We were not able to calculate the 
calibration slope for the PCPT-RC 2.0, as the RC is based on a multinomial logistic 
regression model instead of a binary logistic regression model. 
The discriminative ability for the detection of any PCa was not significantly different  
between the ERSPC RC and the PCPT-RC 2.0 (0.65 vs. 0.66, DeLong test p = 0.39; Table 
3). For PSA alone the AUC for the prediction of any PCa was 0.58. For significant PCa the 
AUC of the ERSPC RC was higher compared to the PCPT-RC 2.0 (0.73 vs. 0.70; Table 4). 
The difference between the two AUCs was statistically significant (DeLong test p=0.043). 
The AUC for the prediction of significant PCa for PSA alone was 0.65.  
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To validate the original three predictions of the PCPT-RC 2.0, the discriminative abilities for 
no PCa, significant PCa and insignificant PCa were also assessed. The analysis revealed 
AUCs of 0.71 (significant versus no PCa), 0.64 (significant versus insignificant PCa) and 
0.59 (insignificant versus no PCa).  
The DCAs revealed that both RCs provided a clinical net benefit in the threshold probability 
range between 18% to 40% for any PCa and in the range between 8% and 40% for 
significant PCa (Figures 3 and 4, respectively). The net benefit was comparable between 
the two RCs for any PCa and somewhat greater for significant PCa if the ERSPC-RC was 
used.  
Our sensitivity analysis revealed a higher detection rate for any PCa (29.4% vs. 18.1%) and 
significant PCa (15.9% vs. 5.9%) in patients receiving a 12-core biopsy (Supplemental 
Table 2). Both RCs overestimated the risk for any and significant PCa in the 6-8 core group 
and underestimated it in the 12-core group. The AUCs for the ERSPC-RC were only slightly 
lower in the 12-core group compared to the 6-8 core group. For the PCPT-RC 2.0 the AUC 
for signifcant PCa was markedly lower in the 12-core group compared to the 6-8 core group 
(0.66 vs. 0.78).   
The analyses of the previous versions of the PCPT-RC revealed that both previous RCs 
overestimated the proportion of men diagnosed with any or significant PCa (Supplemental 
Table 3). Calibration plots for both previous PCPT RC versions confirmed this observation 
showing constant overestimation for both outcomes (Supplemental Figure 1 and 2). The 
PCPT-RC 1.0 with volume showed a better discriminative ability for significant PCa (AUC: 
0.74) than the novel PCPT 2.0 (Supplemental Table 3). 
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Discussion 
Prostate cancer RCs are important prediction tools to overcome the problems that arise 
from the widespread use of PSA screening. The optimal RC would help to minimize the 
number of unnecessary biospies and thereby reduces complications (i.e. systemic 
infections, bleeding) and emotional stress associated with prostate biopsies [23, 24]. 
Furthermore it would reliably predict the risk of being diagnosed with PCa and would give 
accurate predictions of having insignificant or significant disease. Optimization of these 
tools and their implementation into patient counseling and clinical decision making can help 
to decrease overdiagnosis and eventually overtreatment of PCa. Two well known RC for 
PCa risk prediction are the ERSPC and the PCPT RCs. 
The recent updates of the ERSPC and PCPT RCs have been performed to further improve 
their performance [17, 18]. The ERSPC-RC does not include the parameter suspicious 
TRUS lesion anymore but integrates prostate volume estimated by DRE instead of TRUS 
volume [18]. These changes make the RC much more convenient to use in clinical pratice. 
For the novel PCPT-RC 2.0 no variables were added or removed compared to the previous 
version. However, data from more than 1000 biopsies from the PCPT placebo arm were 
added to the original dataset and three instead of two biopsy outcomes are now calculated 
[17]. Despite these updates and modifications the overall performance of the two RCs in 
our dataset was not optimal.   
The present study is the first to externally validate and compare the novel versions of the 
ERSPC-RC and PCPT-RC in a large patient cohort of almost 2000 patients. Both RCs 
showed better performance than PSA alone but less optimistic performance compared to 
their original reports (ERSPC-RC: AUC 0.65 vs. 0.77 for any PCA and 0.73 vs. 0.85 for 
significant PCa; PCPT-RC 2.0: AUC 0.64 vs. median 0.68 for significant vs. insignificant 
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PCA and 0.71 vs. median 0.74 for significant vs. no PCa) [17, 18]. Foley and colleagues 
have recently reported a similar performance of both RCs for the detection of any PCa [19]. 
However, their validation study was conducted in a relatively small cohort of only 337 
patients and RC performance for significant PCa was not assessed. In previous studies 
evaluating and comparing the older versions of the ERSPC and PCPT RCs, the 
performance of the RCs was also less optimistic in the validation cohorts compared to the 
original reports [12-15]. 
It has previously been shown that AUCs of nomograms are often lower in independent 
validations [11]. Differences in the tested populations are likely to account for the 
differences in nomogram performance. Predictor effects have been shown to be different in 
a population setting compared to a clinical setting [25]. Men in our cohort were biospied 
after individualized screening either because of an elevated PSA or a suspicious DRE. In 
contrast, both RCs are based on calculations from data of randomized controlled trials with 
protocol-mandated biopsies. The ERSPC-RC is based on results of a study evaluating 
population-based mass screening. The use of different PSA thresholds (3.0μg/L versus 
2.5μg/L) might be an additional explanation for the differences in performance of the 
ERSPC-RC. Our sensitivity analysis revealed that the higher number of biopsy cores taken 
in more than 50% of our patients had only a minor impact on the RC performance in our 
cohort. The PCPT-RC has been developed from biopsy results of the placebo arm of the 
PCPT. All men were biopsied independently of their PSA value. Differences in the ethnic 
composition of the two cohorts may also explain the different performance. Although only 
3.3% of men in the PCPT were African Americans they accounted for a 2.6-fold higher risk 
of having significant PCa cmpared to Caucasians which constituted the entire population of 
our cohort [9]. In contrast to the ERSPC-RC, the performance of the PCPT-RC 2.0 in our 
cohort was negatively influenced by the higher number of biopsy cores taken, particularly 
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for significant PCa. In addition, our cohort had a relevant amount of pre-biopsied men. 
Although both RCs account for prior negative biopsies this aspect explains the rather low 
detection rate in our cohort compared to others [26, 27]. 
Although a direct comparison between the updated ERSPC-RC and PCPT-RC 2.0 is not 
possible due to the different underlying statistical models, the results of our analysis 
indicate a slightly superior performance of the ERSPC, particularly for the prediction of 
significant PCa. A recent metaanalysis evaluating the older versions of the two RCs also 
revealed a superior performance of the ERSPC [28]. For the novel ERSPC-RC the 
predicted proportion of patients with significant PCa was closer to the observed proportion 
and the AUC for the detection of significant PCa was significantly higher compared to the 
PCPT-RC 2.0. Furthermore, the DCAs revealed a somewhat higher clinical net benefit 
using the ERSPC-RC for significant PCa.  
Risk prediction of significant PCa is a very important feature of PCa RCs because there is 
little evidence that in terms of oncological outcomes, detection and treatment of low-risk 
PCa is beneficial for the patient [29, 30]. Early detection of low risk PCa can reduce quality 
of life due to side effects of treatment or patient anxiety [31]. Thus, personalized risk 
assessment using RC calculating the risk of significant and potentially life-threatining PCa is 
increasingly proposed to counsel patients prior to prostate biopsies and eventually prevent 
overdetection and overtreatment [32, 33].  In clinical practice, when given a probability of 
finding cancer (or significant cancer) by a RC, it should be decided beforehand what 
threshold this probability will need to reach in order to consider biopsy (i.e. the threshold 
probability should be set). This decision is often based on patient co-morbidities, and life-
expectancy, patient preference and risk tolerance. Our data suggests if the threshold 
probability for significant PCa at which one would consider biopsy is between 8-35%, then 
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the ERSPC calculator provides the greatest net benefit, compared to the PCPT risk 
calculator, the "biopsy all" strategy, and the "biopsy nobody" strategy (see Figure 4). We 
expect that for most physicians and most patients, a threshold range between 8 and 35% is 
reasonable to decide whether to perform a biopsy or not, which supports the usefulness of 
this risk calculator. When predicting risk of cancer overall, it is less clear-cut which risk 
calculator provides greater net benefit. Nonetheless, in the era of active surveillance, 
overall cancer risk is a less important trigger for biopsy since Gleason 6 disease would 
often be managed expectantly. Therefore, the decision of whether or not to biopsy, should 
ideally be driven by the probability of harbouring significant cancer, where the ERSPC RC 
was superior to the PCPT 2-0 (AUCs and decision curve analyses). 
Our analysis revealed a significant improvement of the novel PCPT-RC 2.0 compared to 
the PCPT-RC 1.0 with and without prostate volume which constantly overestimated the risk 
of PCa and significant PCa. However, the PCPT-RC 1.0 with volume showed the highest 
AUC for significant PCa of the three PCPT-RCs. It has previously been shown that prostate 
volume is an important variable for the risk prediction of PCa [34]. All ERSPC-RCs include 
prostate volume either in form of TRUS volume or volume estimates based on DRE [18]. 
The superior discriminative ability for significant PCa of the ERSPC-RC and the PCPT-RC-
1.0 with volume indicates the importance of incorporating prostate volume into PCa risk 
prediction tools. 
There are limitations to our study. First, this a retrospective, single-institution study. 
Second, we had to perform adjustments that might have an impact on the results of our 
calculations. Dichotomous outcomes were used for the PCPT-RC 2.0 (rather than three-
category outcomes). Also, prostate volume estimates in our database were based on TRUS 
rather than DRE (ERSPC-RC). Thus, the ERSPC-RC needs further evaluation in studies 
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using true DRE estimates instead of TRUS-measured prostate volumes. Third, the 
homogeneous ethnic composition of our cohort might limit the generalizability of our 
validation. 
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Conclusion 
The use of RCs should be favoured over simple PSA and DRE-based stratification for 
patient counselling and clinical decision making. Our independent external validation 
revealed that both updated RC performed better than PSA alone and predicted significant 
PCa better than any PCa. Prediction of significant PCa, which is important to reduce 
overdiagnosis and overtreatment was superior using the ERSPC-RC. Despite modifications 
of both RCs, risk prediction is still not ideal. Implementation of imaging or novel biomarkers 
might improve the performance of PCa RCs in the future. 
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LEGENDS TO FIGURES 
Figure 1 (A-B): Calibration plots for the ERSPC-RC (A) and the PCPT-RC 2.0 (B) 
predicting any prostate cancer.  
The x-axis shows predicted probabilities by the models and y-axis shows observed 
quintiles. The dashed line represents perfect predictions. The solid line refers to predicted 
vs. observed event rates with grouped patients (quintiles shown by triangles with horizontal 
lines as 95% CI). The spikes along the x-axis depict the number of patients with and without 
prostate cancer.  
 
Figure 2 (A-B): Calibration plots for the ERSPC-RC (A) and the PCPT-RC 2.0 (B) 
predicting significant prostate cancer. For figure explanation see Figure 1. 
 
Figure 3: Decision curve analysis for the prediction of any PCa on biopsy using the 
ERSPC-RC (black dashed line) and the PCPT-RC 2.0 (red dashed line). Decision curves 
examine the theoretical relationship between the threshold probability of PCa biopsy 
outcome and the relative value of false-positive and false-negative results to determine the 
value (net benefit) of a predictive model [22]. The horizontal line along the x-axis assumes 
that no patient will have PCa (ie, no patient should undergo a prostate biopsy), whereas the 
solid gray line assumes that all patients will have PCa (ie, all patients will need to undergo 
prostate biopsy).  
 
Figure 4: Decision curve analysis for the prediction of significant PCa on biopsy using the 
ERSPC-RC (black dashed line) and the PCPT-RC 2.0 (red dashed line). The horizontal line 
along the x-axis assumes that no patient will have significant PCa, whereas the solid gray 
line assumes that all patients will have significant PCa. 
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LEGENDS TO SUPPLEMENTAL FIGURES 
Figure 1 (A-B): Calibration plots for the PCPT-RC 1.0 (A) and PCPT-RC 1.0 with prostate 
volume (B) predicting any prostate cancer.  
The x-axis shows predicted probabilities by the models and y-axis shows observed 
quintiles. The dashed line represents perfect predictions. The solid line refers to predicted 
vs. observed event rates with grouped patients (quintiles shown by triangles with horizontal 
lines as 95% CI). The spikes along the x-axis depict the number of patients with and without 
prostate cancer.  
 
Figure 2 (A-B): Calibration plots for the PCPT-RC 1.0 (A) and PCPT-RC 1.0 with prostate 
volume (B) predicting significant prostate cancer. For figure explanation see Figure 1. 
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TABLES 
 
Table 1 Characteristics of the novel ERSPC and PCPT risk calculators 
   Risk 
calculator Description Variables 
ERSPC1 any and significant2 PCa  PSA, prostate volume (categorical), DRE   
   PCPT-2.0 no PCa, insignificant3 and 
significant2 Pca 
PSA, DRE, family history, previous negative 
biopsy, age, race 
 
1RC 3 for biopsy-naïve patients, RC 4 for men with previous negative biopsy 
2defined as Gleason ≥ 7  3defined as Gleason Score 6   
Abbreviations: PCa: prostate cancer, PSA: prostate-specific antigen, DRE: digital rectal examination 
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Table 2: Clinical characteristics of patient cohort and differences between patients with and 
without a positive prostate biopsy 
        
Variable All Patients Negative Biopsy Positive Biopsy P-value* 
             
Number of patients 
 
1996 (100) 1513 (76) 483 (24)   
Age at biopsy (years) 
 
63 (58 - 67) 62 (57 - 67) 65 (60 - 69) <0.001 
PSA (ng/ml) 
 
 5.0 (3.4 -7.6) 4.8 (3.3 - 7.3) 5.6 (3.7 – 9.0) <0.001 
Suspicious DRE 
 
386 (19) 241 (16) 145 (30) <0.001 
Prostate volume (mL) 
 
 40.0 (30.0 - 
55.0) 40.0 (30 - 55) 36.0 (28 - 50) <0.001 
 
<30cm3 429 (22) 302 (20) 127 (27)   
 30-49cm
3 860 (44) 643 (43) 217 (47)   
 ≥50cm
3 654 (34) 535 (36) 119 (26)   
Family history of prostate 
cancer 
 
40 (2) 21 (1) 19 (4) <0.001 
Race Caucasian 1984 (99) 1504 (99) 480 (99) >0.99 
Prior negative biopsy  845 (42) 707 (47) 138 (29) <0.001 
Total cores taken at 
biopsy 6 139 (7) 117 (8) 22 (4) <0.001  
 
8 777 (39) 633 (42) 144 (30)   
 
12 1080 (54) 763 (50) 317 (66)   
Prostate cancer 
 
483 (24) - -     
Significant prostate 
cancer1   
226 (11) - - 
    
        Values are presented as median (interquartile range) or number (percent)  
* P-values in bold indicate a statistically significant difference between the two groups (negative biopsy vs. positive biopsy).  
Abbreviations: PSA: prostate-specific antigen, DRE: digital rectal examination 
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Table 3: Validation results 
 ERSPC 
 
PCPT- 2.0 
Any prostate cancer   
Observed proportion (%) 
Predicted proportion (%) 
24 
22.2 
24 
24.3 
Calibration slope 0.47 -1 
AUC 0.65 0.66 
Significant prostate cancer   
Observed proportion (%) 
Predicted proportion (%) 
11  
9.4 
11  
8.6 
Calibration slope 0.56 -1 
AUC 0.73 0.70 
AUC: Area under the receiver operating characteristic curve 
1 The PCPT-2.0 risk calculator is based on a multinomial logistic regression model instead of a  
 binary logistic regression model 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
